share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/08/28 06:09

Moomoo AI 已提取核心信息

Transcode Therapeutics received two deficiency notices from Nasdaq regarding potential delisting. The first notice on August 13 cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 to August 12. The company is ineligible for the standard 180-day compliance period due to two reverse stock splits exceeding a 250:1 ratio in the past two years.The second notice on August 15 addressed non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported equity of $1.32 million as of June 30. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma equity to $3.7 million, there is no guarantee Nasdaq will consider this adjustment.The company has appealed both delisting determinations, with the delisting action temporarily stayed pending a Nasdaq Hearings Panel review scheduled for October 1, 2024. There is no assurance that additional extension will be granted or that compliance will be regained for continued Nasdaq Capital Market listing.
Transcode Therapeutics received two deficiency notices from Nasdaq regarding potential delisting. The first notice on August 13 cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 to August 12. The company is ineligible for the standard 180-day compliance period due to two reverse stock splits exceeding a 250:1 ratio in the past two years.The second notice on August 15 addressed non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported equity of $1.32 million as of June 30. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma equity to $3.7 million, there is no guarantee Nasdaq will consider this adjustment.The company has appealed both delisting determinations, with the delisting action temporarily stayed pending a Nasdaq Hearings Panel review scheduled for October 1, 2024. There is no assurance that additional extension will be granted or that compliance will be regained for continued Nasdaq Capital Market listing.
Transcode Therapeutics 收到来自纳斯达克的两份退市通知。第一份通知于8月13日发出，指出从7月1日到8月12日，连续30个交易日未能维持最低1.00美元的买盘价格要求。由于过去两年内进行过两次超过250:1比例的拆股并股，该公司不符合标准的180天合规期。第二份通知于8月15日发出，关于不符合最低股东权益要求250万美元的通知，因为截至6月30日，该公司报告的股东权益为132万美元。尽管2024年7月的股权发行增加了大约240万美元的净收益，使得形式上的股东权益达到370万美元，但并没有保证纳斯达克会考虑这一调整。该公司已对这两项退市决定提出上诉，退市行动在等待定于2024年10月1日的纳斯达克听证小组审查期间暂时中止。并不能保证会获得额外的延期，或者能恢复合规以继续纳斯达克资本市场的上市。
Transcode Therapeutics 收到来自纳斯达克的两份退市通知。第一份通知于8月13日发出，指出从7月1日到8月12日，连续30个交易日未能维持最低1.00美元的买盘价格要求。由于过去两年内进行过两次超过250:1比例的拆股并股，该公司不符合标准的180天合规期。第二份通知于8月15日发出，关于不符合最低股东权益要求250万美元的通知，因为截至6月30日，该公司报告的股东权益为132万美元。尽管2024年7月的股权发行增加了大约240万美元的净收益，使得形式上的股东权益达到370万美元，但并没有保证纳斯达克会考虑这一调整。该公司已对这两项退市决定提出上诉，退市行动在等待定于2024年10月1日的纳斯达克听证小组审查期间暂时中止。并不能保证会获得额外的延期，或者能恢复合规以继续纳斯达克资本市场的上市。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！